Kyle Piskel Sells 18,672 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CFO Kyle Piskel sold 18,672 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total transaction of $245,910.24. Following the completion of the sale, the chief financial officer owned 259,840 shares in the company, valued at $3,422,092.80. This represents a 6.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Kyle Piskel also recently made the following trade(s):

• On Wednesday, February 4th, Kyle Piskel sold 2,145 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $18.46, for a total transaction of $39,596.70.
• On Monday, January 12th, Kyle Piskel sold 4,290 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $18.00, for a total transaction of $77,220.00.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ ADPT traded up $0.72 on Friday, hitting $13.17. The company’s stock had a trading volume of 3,902,529 shares, compared to its average volume of 1,832,300. The stock has a 50 day moving average of $16.55 and a 200-day moving average of $15.85. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of -32.92 and a beta of 2.19. Adaptive Biotechnologies Corporation has a 12-month low of $6.68 and a 12-month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. During the same period last year, the company posted ($0.23) EPS. The company’s revenue was up 51.0% on a year-over-year basis. Sell-side analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ADPT shares. BTIG Research boosted their price target on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They issued an “equal weight” rating and a $21.00 target price for the company. Finally, Guggenheim upped their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a report on Monday, January 26th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Adaptive Biotechnologies has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several hedge funds have recently made changes to their positions in ADPT. Ameriprise Financial Inc. grew its position in shares of Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after purchasing an additional 2,731,648 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Adaptive Biotechnologies by 303.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after buying an additional 3,299,635 shares during the period. Westfield Capital Management Co. LP purchased a new position in Adaptive Biotechnologies during the fourth quarter worth about $65,942,000. Geode Capital Management LLC boosted its stake in Adaptive Biotechnologies by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock worth $57,041,000 after buying an additional 110,825 shares during the last quarter. Finally, State Street Corp boosted its stake in Adaptive Biotechnologies by 3.3% in the 4th quarter. State Street Corp now owns 3,181,644 shares of the company’s stock worth $51,670,000 after buying an additional 102,362 shares during the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.